FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool/File Photo
Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker’s drug Victoza.
COPENHAGEN: Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker’s drug Victoza.
“We can confirm that Novo Nordisk has filed a lawsuit against Mylan for patent infringement of Victoza,” the company said in an e-mail.
Advertisement
Advertisement
The news was first reported by Bloomberg.
(Reporting by Andreas Mortensen; editing by Jason Neely)
